Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: A broad market meltdown appears to be to blame for Star's suffering this time. For long-term investors, it's an opportunity to get in at … 28 times book value and 566 tomes sales. Ouch.
Now what: Bullish investors will rightly counter that Star's CigRX dietary supplements are no different from any in-development drug and that the potential payoff for reducing or eliminating cigarette cravings could be in the billions. In that sense, today's selloff could be a non-event. Do you agree? Disagree? Weigh in using the comments box below.
Interested in more info on Star Scientific?Add it to your watchlist.